ROS1 and non-small cell lung carcinoma: The prognosis of resected stage IIIA-N2 NSCLC is unsatisfactory, but the higher frequency of ROS1 rearrangement in stage IIIA-N2 adenocarcinoma cases reminds that targeted therapy will be a new treatment strategy.